Bright Minds Biosciences Inc. announced on March 4, 2025, the expansion of its Scientific Advisory Board (SAB) to include five renowned leaders in epilepsy research. The new members are Dennis Dlugos, MD, MSCE; Jacqueline French, MD; Terrence O'Brien, MD; Jo Sourbron, MD, PhD, MPharm; and Joseph Sullivan, MD.
These individuals bring decades of experience in epilepsy drug development and research, which will support the company's clinical focus on epilepsy. Their collective expertise is expected to provide valuable guidance for Bright Minds' pipeline, particularly for its lead candidate BMB-101.
The addition of these experts underscores Bright Minds' commitment to addressing drug-resistant epilepsy and other central nervous system disorders. This strategic enhancement to the SAB aims to strengthen the scientific foundation and clinical development strategies of the company.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.